CAMBRIDGE, Mass. — CapeStart Inc. has announced a significant new release of its generative AI platform, MadeAi, at the ISPOR Montreal 2025 Conference. The updated platform promises to help life science organizations scale faster and increase productivity by cutting literature review times in half while maintaining high accuracy in data extraction and synthesis.
Originally launched in November 2024, the MadeAi platform—specifically its MadeAi-LR solution—has become a central tool for conducting systematic literature reviews, clinical evidence reports, meta-analyses, and other types of clinical literature assessments. The newest version introduces several advanced features designed to support increasingly complex review needs and regulatory demands.
Among the key enhancements is the introduction of AI-aided Review and AI as Reviewer capabilities, allowing human reviewers to work alongside AI to expedite screening tasks without compromising quality. The platform also now supports an expanded screening model with customizable criteria, including user-defined options for novel research parameters.
MadeAi further enhances its extraction capabilities with both summary-level and arm-level options. The summary-level extraction gives users a consolidated view of key study information for internal research, while the arm-level extraction offers detailed outcome data across different study groups. These tools are designed to improve clarity and efficiency during the review process.
Another major feature is the integration of AI Agent-Enhanced Extraction, which enables information to be drawn from not only text but also tables, graphs, and figures. Additionally, a built-in Quality Appraisal function allows users to assess risk-of-bias and visualize results through intuitive tables and charts.
Developed in collaboration with top pharmaceutical companies, MadeAi-LR provides full sourcing and attribution, ensuring transparency in research decisions. By centralizing the literature review process, the platform helps pharmaceutical, biotech, and medtech teams reduce manual workload, redirect resources toward high-value work, and ultimately accelerate the pace of scientific innovation.
CapeStart CEO Gaugarin Oliver emphasized the platform’s growing value for clients facing complex research demands. “MadeAi-LR customers are completing more literature reviews in less time and seeing immediate ROI,” Oliver said. “Our latest release supports dynamic aspects of literature review research—including AI as Reviewer, arm-level extraction, and quality appraisals—so teams can scale faster and focus on what matters most: advancing science.”
Since its debut, MadeAi has received multiple accolades for its contributions to AI in healthcare. The platform earned a Stevie Award in the 21st Annual International Business Awards, was recognized by PM360 as a 2024 Innovator in Generative AI, and most recently won the 2025 Artificial Intelligence Excellence Award from the Business Intelligence Group.
